Welcome to the ViiV Exchange

for UK Healthcare Professionals

LOGIN REGISTER

In the management of HIV, times are changing

Are your treatment decisions for your virologically suppressed patients changing with them?

LEARN MORE ABOUT 2‑DRUG REGIMEN

 

 

 

The first single-pill, 2-drug regimen for your virologically suppressed patients

 

LEARN MORE
CROI

CROI 2019

LEARN MORE

GLASGOW 2018

Learn more

OUR MEDICINES

LEARN MORE

In the management of HIV, times are changing

Are your treatment decisions for your virologically suppressed patients changing with them?

LEARN MORE ABOUT 2DR

The first single-pill, 2-drug regimen for your virologically suppressed patients.

LEARN MORE

Latest Videos

Latest 2DR data from Glasgow 2018

Play this video
Duration
2:59
Preparation date Oct 2018
annemiek-time-to-rethink

Is it time to rethink the way we treat HIV?

Play this video
Duration
3:06
Preparation date Nov 2018
Patient Benefits

See how a 2DR can benefit your patients

Play this video
Duration
1:25
Preparation date May 2018

Our medicines

JULUCA▼

JULUCA (dolutegravir/rilpivirine) is indicated for HIV-1 virologically suppressed adults on a stable regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI.

 

Read more about JULUCA

TIVICAY▼

Tivicay (dolutegravir) is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age.

Read More About TIVICAY

View all our medicines

UK/DTGP/0002/17(8) | November 2018